Anika Announces Third Quarter 2024 Results Conference Call Date
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company specializing in early intervention orthopedics, has announced the date for its Third Quarter 2024 Results Conference Call. The company will release its financial results before the market opens on Thursday, October 31, 2024. This will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights.
Interested parties can access the conference call by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and using the conference ID number 31842. Additionally, a live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website at www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion.
Anika Therapeutics (NASDAQ: ANIK), un'azienda globale specializzata nella preservazione delle articolazioni e interventi ortopedici precoci, ha annunciato la data per la sua Conference Call sui Risultati del Terzo Trimestre 2024. L'azienda pubblicherà i suoi risultati finanziari prima dell'apertura del mercato, giovedì 31 ottobre 2024. Questo sarà seguito da una conference call alle 8:30 a.m. ET per discutere i risultati e i punti salienti dell'attività.
Le parti interessate possono accedere alla conference call componendo il numero 1-800-717-1738 (numero verde nazionale) o 1-646-307-1865 (internazionale) utilizzando il numero ID conferenza 31842. Inoltre, una webcast audio dal vivo e i materiali di presentazione saranno disponibili nella sezione Relazioni con gli Investitori del sito web di Anika all'indirizzo www.anika.com. La registrazione della chiamata sarà archiviata e accessibile sullo stesso sito poco dopo la conclusione.
Anika Therapeutics (NASDAQ: ANIK), una empresa global especializada en la preservación de articulaciones y ortopedia de intervención temprana, ha anunciado la fecha de su Conferencia sobre Resultados del Tercer Trimestre de 2024. La compañía publicará sus resultados financieros antes de la apertura del mercado el jueves 31 de octubre de 2024. Esto será seguido por una conferencia telefónica a las 8:30 a.m. ET para discutir los resultados y los aspectos destacados del negocio.
Las partes interesadas pueden acceder a la conferencia telefónica marcando 1-800-717-1738 (número gratuito nacional) o 1-646-307-1865 (internacional) y utilizando el número de ID de la conferencia 31842. Además, habrá una transmisión de audio en vivo y materiales de presentación disponibles en la sección de Relaciones con Inversores del sitio web de Anika en www.anika.com. La llamada se archivará y estará accesible en el mismo sitio poco después de su conclusión.
Anika Therapeutics (NASDAQ: ANIK), 조기 개입 정형외과를 전문으로 하는 글로벌 관절 보존 회사가 2024년 3분기 실적 컨퍼런스 콜 날짜를 발표했습니다. 회사는 2024년 10월 31일 목요일에 시장이 열리기 전에 재무 결과를 발표할 예정입니다. 이어서 오전 8:30 ET에 결과와 비즈니스 하이라이트에 대해 논의하는 컨퍼런스 콜이 있을 것입니다.
관심 있는 분들은 1-800-717-1738 (국내 무료) 또는 1-646-307-1865 (국제)로 전화하여 컨퍼런스 ID 번호 31842를 입력하여 컨퍼런스 콜에 접속할 수 있습니다. 또한, Anika의 웹사이트 www.anika.com의 투자자 관계 섹션에서 실시간 오디오 웹캐스트 및 관련 발표 자료를 이용할 수 있습니다. 콜은 종료 후 곧바로 같은 웹사이트에 아카이브되어 접근할 수 있습니다.
Anika Therapeutics (NASDAQ: ANIK), une entreprise mondiale spécialisée dans la préservation des articulations et l'orthopédie d'intervention précoce, a annoncé la date de sa conférence téléphonique sur les résultats du troisième trimestre 2024. La société publiera ses résultats financiers avant l'ouverture du marché le jeudi 31 octobre 2024. Cela sera suivi d'une conférence téléphonique à 8h30 ET pour discuter des résultats et des faits saillants de l'activité.
Les parties intéressées peuvent accéder à la conférence téléphonique en composant le 1-800-717-1738 (numéro sans frais national) ou le 1-646-307-1865 (international) et en utilisant le numéro d'identification de la conférence 31842. De plus, un webinaire audio en direct ainsi que des supports de présentation seront disponibles dans la section Relations avec les investisseurs du site web d'Anika à l'adresse www.anika.com. L'appel sera archivé et accessible sur le même site peu après sa conclusion.
Anika Therapeutics (NASDAQ: ANIK), ein globales Unternehmen für Gelenkserhaltung, das auf frühzeitige Eingriffe in der Orthopädie spezialisiert ist, hat das Datum für seinen Konferenzanruf zu den Ergebnissen des dritten Quartals 2024 bekannt gegeben. Das Unternehmen wird seine finanziellen Ergebnisse am Donnerstag, den 31. Oktober 2024, vor Markteröffnung veröffentlichen. Dem wird ein Konferenzanruf um 8:30 Uhr ET folgen, um die Ergebnisse und geschäftlichen Highlights zu besprechen.
Interessierte Parteien können auf den Konferenzanruf zugreifen, indem sie 1-800-717-1738 (gebührenfrei innerhalb der USA) oder 1-646-307-1865 (international) wählen und die Konferenz-ID-Nummer 31842 verwenden. Darüber hinaus wird ein Live-Audio-Webcast und ergänzende Präsentationsmaterialien im Bereich für Investorenbeziehungen auf der Webseite von Anika unter www.anika.com verfügbar sein. Der Anruf wird archiviert und wird kurz nach seinem Abschluss auf derselben Webseite zugänglich sein.
- None.
- None.
BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 31842. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
FAQ
When will Anika Therapeutics (ANIK) release its Q3 2024 financial results?
What time is Anika's (ANIK) Q3 2024 earnings conference call scheduled for?
How can investors access Anika's (ANIK) Q3 2024 earnings conference call?
Where can investors find Anika's (ANIK) Q3 2024 earnings presentation materials?
